Skip to main content

Table 2 Multiple linear regression of factors associated with lnALC nadir

From: Characterization and dosimetric predictors for absolute lymphocyte count changes during neoadjuvant chemoradiotherapy with or without pembrolizumab for esophageal squamous cell carcinoma: an analysis of a prospective cohort

Variable

lnALC nadir

β(95%CI)

Adjusted R2

p

Thoracic vertebrae body

   

 TVB V20

-0.0065

0.056

0.0005

 TVB V10

-0.011

0.14

< 0.001

 TVB V5

-0.012

0.16

< 0.0001

 Mean TVB dose

-0.034

0.135

< 0.0001

Mean cardiopulmonary dose

-0.061

0.011

< 0.0001

Mean whole body dose

-0.1

0.063

0.0002

Ribs

   

 V40

0.0004

0.0001

0.90

 V30

-0.0002

0.000

0.96

 V20

-0.0034

0.0035

0.39

 V10

-0.0082

0.018

0.049

 V5

-0.0088

0.0358

0.0053

Mean ribs dose

-0.077

0.11

< 0.0001

Mean sternum dose

-0.003

0.0017

0.055

Spleen dose

   

 V40

-0.0056

0.013

0.094

 V30

-0.0057

0.032

0.0088

 V20

-0.0063

0.074

0.0001

 V10

-0.0062

0.12

< 0.0001

 V5

-0.0059

0.16

< 0.0001

Mean spleen dose

-0.031

0.15

< 0.0001

  1. Abbreviations: TVB: Thoracic vertebrae body; BMI: body mass index
  2. *Models included one dosimetric parameter and each of the following covariates: age (continuous), BMI (continuous), nCRT regimen, Sex and tumor length (continuous)
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us